Our Unified Platform simplifies trial operations with fully integrated consenting, data collection, remote study visits, and more. See how sites and patients benefit: https://hubs.li/Q02JXRSF0
Signant Health
Pharmaceutical Manufacturing
Blue Bell, Pennsylvania 111,855 followers
The Evidence Generation Company
About us
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.
- Website
-
http://www.signanthealth.com
External link for Signant Health
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Blue Bell, Pennsylvania
- Type
- Privately Held
- Specialties
- clinical trial software, eCOA, eConsent, IRT, Clinical Supply Optimization, Patient Engagement, Rater Training, Data Quality, Analytics, Scientific Consulting, and Clinical Consulting
Locations
Employees at Signant Health
-
John Hughes
Business Development and Operations Executive - enabling revenue growth through strategy, process, technology and culture.
-
Markku Lukkarinen
Senior UX Designer at Weasel Software
-
Joanne Kondan
Finance and Operations Leader, Specializing in Operational Effectiveness
-
Konstantin Kondakov
SRE / CloudOps / DevOps / TechOps / WebOps "hands-on"senior manager
Updates
-
For CROs only: Get ready to see how a truly unified #eClinical platform enhances your competitive advantage with fast study setups and site-friendly features like single sign-on. Save your spot: https://hubs.li/Q02JPw0Q0
-
-
Oncology trial designs are often intricate, encompassing various disease cohorts and treatment arms with varying administration cycles. Discover how Signant SmartSignals® solutions including #eCOA, #RTSM, and #eConsent streamline every step of your #oncologyresearch journey: https://hubs.li/Q02JDmJw0
-
Look for this team at #AAIC2024 to learn about cognitive assessments and endpoint reliability solutions for #AlzheimersResearch. Stop by booth 610 or schedule time: https://hubs.li/Q02Jt3tw0 Matthew Cordaro, MBA Linda Berkowitz Maria Kerwin Sayaka Machizawa, Psy.D. Ashley Dawn Gates Jessica Stenclik, PhD, ABPP Brian Mcallister Sandra Marticio david miller Helen Brooker Jennifer Betz
-
-
Evaluate cognitive function and safety in phase I #clinicaltrials with Signant SmartSignals® CDR System® to gain critical information for decision-making about safety, tolerability, dosage, and more: https://hubs.li/Q02JqwSF0
-
-
We support psychedelic #clinicaltrials with the methodological rigor and familiarity with the evolving regulatory landscape necessary to gain approvals. Explore our solutions and experience:➡️ https://hubs.li/Q02HM-2c0
-
-
Explore how computerized cognitive assessments in #oncologytrials revolutionize understanding Cancer-Related Cognitive Impairment (CRCI), transform trial protocols, and inform targeted interventions in our latest blog post by Viani Figueroa, PhD: https://hubs.li/Q02HtCfc0
-
-
Attention CROs! In our upcoming webinar, discover how a unified #eClinical platform gives you a competitive edge, enhances your offerings to sponsors, and streamlines site operations. Save your spot: https://lnkd.in/dPaNfbJV
-
-
Despite the potential benefits to patients, providers, and pharmaceutical companies, the absence of labeling related to Patient-Reported Outcome Measures has been striking. In this article in DIA's Global Forum, Anthony Todd Everhart, MD examines the challenges with PROMs in #cancertrials and proposes collaborative ways to overcome them: https://hubs.li/Q02GYbrR0
-
-
Look for us at #AAIC24 where we're discussing the role of cognitive assessments in #AlzheimersResearch and sharing interesting findings in these posters: 🌍 Geo-cultural Variation in MMSE Score Changes in Alzheimer's Trials 📊 MMSE and CDR Score Changes in Multinational Alzheimer's Trials 📑 Impact of Rater Change on MMSE Data: A Post-Hoc Analysis 📉 Impact of Site Size on Data Quality in Early Alzheimer's Disease Clinical Trials Meet our experts and get resources: https://hubs.li/Q02GLX_S0